Assembly bio selects fourth hbv core inhibitor candidate for advancement into clinical development

South san francisco, calif., aug. 18, 2021 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis b virus (hbv), today announced it has selected a fourth core inhibitor candidate, abi-4334 (4334), that has been optimized for potency, to advance into clinical development. the company is conducting preclinical work, with the aim of completing regulatory filings and initiating clinical studies as soon as possible in 2022.
ASMB Ratings Summary
ASMB Quant Ranking